Kiniksa Advances KPL-387 Study for Recurrent Pericarditis: What Investors Should Know

Kiniksa Pharmaceuticals Ltd. Class A (KNSA) announced an update on their ongoing clinical study.

Kiniksa Pharmaceuticals recently announced updates to its Phase 2 clinical study, ‘A Phase 2 Posology Study With Long-Term Extension in Participants With Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy From Standard Therapies.’ This study aims to evaluate the efficacy and safety of transitioning patients with recurrent pericarditis from existing therapies to KPL-387 monotherapy, offering potential new hope for managing this condition.

KPL-387, an experimental drug administered via subcutaneous injection, is being tested to replace standard therapies for recurrent pericarditis with a safer, longer-term solution. The study also includes a long-term extension phase for participants to continue on the drug as needed.

The study is being conducted as a non-randomized, single-group trial with no masking, focusing on treatment outcomes. It aims to test the intervention over 16 weeks initially, followed by an extension phase lasting up to 24 months.

While this study is not yet recruiting as of December 2025, it is expected to play a critical role in shaping future treatment options. Key dates include the first submission on December 2, 2025, with the latest update on December 15, 2025.

This new study announcement has piqued interest in Kiniksa Pharmaceuticals, as successful results could enhance their pipeline value and stock performance, especially in a competitive pharmaceutical landscape addressing heart disease treatments. Investors will be closely watching for progress and potential commercial breakthroughs.

The study remains ongoing, with detailed insights available on the ClinicalTrials portal.

To learn more about KNSA’s potential, visit the Kiniksa Pharmaceuticals Ltd. Class A drug pipeline page.